Study wrapper · #891
Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study.
Buse JB, Bajaj HS, Dalskov SM, et al. The lancet. Diabetes & endocrinology. 2026.
DOI: 10.1016/s2213-8587(26)00125-7PubMed: 42251859
Editor's note
This large active-controlled phase 3 RCT directly compared cagrilintide-semaglutide against semaglutide monotherapy, giving a clean read on semaglutide as a comparator arm. The combination was statistically superior for HbA1c, though the absolute difference of 0.16 percentage points is small. Novo Nordisk-funded; the semaglutide 2.4 mg arm itself performed strongly, which is directly relevant.
Plain-language abstract
In this large phase 3 trial, cagrilintide-semaglutide produced modestly greater HbA1c reduction than semaglutide 2.4 mg alone in people with type 2 diabetes.
Related coverage
Mixed
Amylin and the renin-angiotensin system: risk or opportunity in amylin-based therapy?
Lancet (London, England)n=——2026
Supported
Co-agonism of GLP-1R and CTR/AMYR in the lateral dorsal tegmental nucleus produces additive effects on homeostatic and motivated feeding.
Physiology & behaviorn=——2026
Supported
Maximizing weight loss with cagrisema: a systematic review and GRADE-assessed meta-analysis of randomized controlled trials.
Naunyn-Schmiedeberg's archives of pharmacologyn=——2026